stents

indicación de tratamiento con estatinas

Anti-Lipid Therapy in PCI Patients: Monotherapy with Statins or Combination?

According to several studies, in patients with high-risk atherosclerotic disease, such as those affected by coronary artery disease, achieving target LDL levels through high-intensity statin therapy has been shown to lead to a significant reduction in long-term cardiovascular events. Therefore, the management of dyslipidemia has become a fundamental pillar of secondary prevention. However, reaching such<a href="https://solaci.org/en/2023/10/04/anti-lipid-therapy-in-pci-patients-monotherapy-with-statins-or-combination/" title="Read more" >...</a>

IAM y múltiples vasos, ¿podemos realizar un solo procedimiento?

AMI and Multivessel Disease: Can We Perform a Single Procedure?

Percutaneous coronary intervention (PCI) is considered the treatment of choice in ST-segment elevation myocardial infarction (STEMI). However, it is widely acknowledged that, in many cases, there are significant lesions in other coronary arteries. Previous randomized studies have shown that complete revascularization in a second procedure is more beneficial than intervention only in the culprit artery.<a href="https://solaci.org/en/2023/09/19/ami-and-multivessel-disease-can-we-perform-a-single-procedure/" title="Read more" >...</a>

Diabetes y enfermedad vascular periférica: viejas drogas con nueva evidencia

BIFURCAT Registry: Long Term Diabetes Impact on Bifurcations PCI Outcomes

The impact of diabetes in patients with coronary artery disease (CAD) are well known, and after percutaneous coronary intervention (PCI), outcomes tend to be less favorable, with higher restenosis rate, repeat myocardial infarction (MI) and stent thrombosis. Despite the development of drug eluting stents, procedures and techniques, treating bifurcation lesions in diabetic patients still show<a href="https://solaci.org/en/2023/09/15/bifurcat-registry-long-term-diabetes-impact-on-bifurcations-pci-outcomes/" title="Read more" >...</a>

Nueva y discrepante información sobre los vasos no culpables en el infarto

Is Complete Revascularization Really Necessary after AMI in the Elderly?

The population over 75 is growing gradually, which entails an increase in acute myocardial infarction (AMI) in this group. As we all know, it is fairly common for AMI to present with multivessel disease.&nbsp; It has been shown that younger patients will benefit from complete revascularization vs. a simple resolution of the culprit vessel. However,<a href="https://solaci.org/en/2023/09/13/is-complete-revascularization-really-necessary-after-ami-in-the-elderly/" title="Read more" >...</a>

Resonancia vs FFR en lesiones no culpables del infarto

OCT-Guided PCTA: Does It Offer any Benefits?

For many years, percutaneous transluminal coronary angioplasty (PCTA) has expanded significantly worldwide. However, despite the demonstrated advantages of intravascular ultrasound (IVUS) in terms of minimal luminal area, reduced cardiovascular events, and restenosis, its use is not very common due to various reasons. On the other hand, optical coherence tomography (OCT) offers even higher resolution than<a href="https://solaci.org/en/2023/09/12/oct-guided-pcta-does-it-offer-any-benefits/" title="Read more" >...</a>

ESC 2023

ESC 2023 | STOPDAPT-3 

Short Dual antiplatelet therapy (DAPT), one to three months, followed by P2Y12 inhibitor monotherapy has been shown to reduce bleeding events without increased cardiovascular events vs. standard DAPT, according to guidelines.&nbsp; However, the rate of major bleeding within the first month after procedure remains significant when using these strategies.&nbsp; The use of aspirin-free therapies (ASA)<a href="https://solaci.org/en/2023/08/29/esc-2023-stopdapt-3-2/" title="Read more" >...</a>

ESC 2023

ESC 2023 | OCTOBER TRIAL: Should We Begin to Consider OCT for Bifurcation Lesions?

The OCTOBER Study randomized 1201 patients with bifurcation lesions in a 1:1 ratio to undergo percutaneous transluminal coronary angioplasty (PTCA) guided by optical coherence tomography (OCT) or by angiography. The primary endpoint (PEP) was major adverse cardiovascular events (MACE) over a 2-year period. Group characteristics were similar. The average patient age was 66 years, most<a href="https://solaci.org/en/2023/08/29/esc-2023-october-trial-should-we-begin-to-consider-oct-for-bifurcation-lesions/" title="Read more" >...</a>

Scientific Coverage SOLACI-SBHCI 2023

Congress SOLACI-SBHCI 2023 &#8211; Day 1 Summary

Today, the SOLACI SBHCI 2023 Congress, the largest interventional cardiology event in Latin America, organized by the Latin American Society of Interventional Cardiology (SOLACI) and the Brazilian Society of Hemodynamics and Interventional Cardiology (SBHCI), began in Rio de Janeiro. The event is taking place between August 2nd August 4th at the Windsor Convention Center &amp;<a href="https://solaci.org/en/2023/08/03/congress-solaci-sbhci-2023-day-1-summary/" title="Read more" >...</a>

Device Effectiveness for Femoropopliteal Artery Disease Treatment: Analysis of K-VIS ELLA Registry

Endovascular treatment of lesions in femoropopliteal territory (FPA) has become the main therapeutic option, seeing as it is less invasive and has faster recovery. It has used different devices, such as conventional bare metal stents (BMS), balloon angioplasty (POBA), and drug coated balloons (DCB), as well as drug eluting stents (DES). However, real world data<a href="https://solaci.org/en/2023/07/24/device-effectiveness-for-femoropopliteal-artery-disease-treatment-analysis-of-k-vis-ella-registry/" title="Read more" >...</a>

Abbott Vascular suspendió la venta de Absorb en todos los países

ABSORB IV – Improving Bioresorbable Scaffolds: A Long Road

5-year followup of bioresorbable scaffolds in selected and better prepared lesions (ABSORB IV).&nbsp; Historically, when comparing previously used therapies, such as conventional balloon angioplasty (BA) against bare metal stent (BMS) and later against drug eluting stent (DES) implantation, we see significantly improved outcomes. These advances have shown reduced recoil and more effective restenosis inhibition, compared<a href="https://solaci.org/en/2023/07/19/absorb-iv-improving-bioresorbable-scaffolds-a-long-road/" title="Read more" >...</a>

Top